Fisetin Attenuates Doxorubicin-Induced Cardiomyopathy In Vivo and In Vitro by Inhibiting Ferroptosis Through SIRT1/Nrf2 Signaling Pathway Activation

Li, Danlei; Liu, Xiaoman; Pi, Wenhu; Zhang, Yang; Yu, Lei; Cheng, Xu; Sun, Zhenzhu; Jiang, Jianjun

doi:10.3389/fphar.2021.808480

Public

Fisetin Attenuates Doxorubicin-Induced Cardiomyopathy In Vivo and In Vitro by Inhibiting Ferroptosis Through SIRT1/Nrf2 Signaling Pathway Activation

Published in Frontiers in Pharmacology • Feb 22, 2022

Authors:

Danlei Li

Xiaoman Liu

Wenhu Pi

Abstract

Doxorubicin (DOX) is an anthracycline antibiotic that is used extensively for the management of carcinoma; however, its clinical application is limited due to its serious cardiotoxic side effects. Ferroptosis represents iron-dependent and reactive oxygen species (ROS)-related cell death and has been...

Subject

Fisetin

Pharmacology

Cardiotoxicity

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!